Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Non-Current Liabilities data on file, last reported at $13.3 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $13.3 million, down 4.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (down 4.98% YoY), and the FY2025 annual result was $17.1 million, down 2.29% from the prior year.
• Total Non-Current Liabilities eased to $13.3 million in Q1 2026 per FULC's latest filing, from $17.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $34.3 million in Q2 2022 and troughed at $13.3 million in Q1 2026.
• A 5-year average of $21.0 million and a median of $20.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities advanced 17.41% in 2022, then declined 29.63% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $27.5 million in 2022, then dropped by 19.03% to $22.3 million in 2023, then retreated by 21.6% to $17.5 million in 2024, then slipped by 2.29% to $17.1 million in 2025, then decreased by 22.34% to $13.3 million in 2026.
• Business Quant data shows FULC's Total Non-Current Liabilities at $13.3 million in Q1 2026, $17.1 million in Q4 2025, and $16.3 million in Q3 2025.